No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US OptionsDetailed Quotes
JNJ241220P142000
- 0.59
- +0.38+180.95%
15min DelayClose Dec 16 16:00 ET
0.59High0.10Low
0.15Open0.21Pre Close108 Volume94 Open Interest142.00Strike Price2.50KTurnover20.09%IV1.70%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier4DDays to Expiry0.59Extrinsic Value100Contract SizeAmericanOptions Type-0.2573Delta0.1076Gamma306.06Leverage Ratio-0.1240Theta-0.0037Rho-78.75Eff Leverage0.0482Vega
Intraday
- 5D
- Daily
News
Express News | J&J - Currently Approved Intravenous Formulation of Rybrevant (Amivantamab-Vmjw) Is Not Impacted by Crl
Express News | J&J - FDA Issued Crl for Bla for Combination of Amivantamab & Recombinant Human Hyaluronidase for Subcutaneous Amivantamab
Dow's 111-Point Drop Led By Losses For UnitedHealth, Verizon Shares
Moderna Remains the Most Shorted Among S&P 500 Healthcare Stocks in November
Express News | J&J: Submits Application Seeking U.S. FDA Approval of Simponi® (Golimumab) for Treatment of Pediatric Ulcerative Colitis
Johnson & Johnson is suing a division of Cigna, accusing it of misappropriating a financial aid fund.
On December 16, Gleno Exchange reported that Johnson & Johnson has filed a lawsuit against a division of Cigna, accusing the medical insurance company of collaborating with pharmaceutical benefit managers to steal Johnson & Johnson's financial assistance funds, which are specifically designated for patients using some of Johnson & Johnson's high stock price drugs.